NewCardio to Perform First Revenue-Generating QT Study Using QTinno


Company News Release

NewCardio, Inc.

, (OTC Bulletin Board: NWCI) a cardiac diagnostic technology provider, announced that a global biopharmaceutical services provider has signed a MSA, licensing NewCardio's QTinno™ software solution to enhance its delivery of fully automated cardiac safety analyses for early phase QT studies. The CRO is expected to deploy QTinno in several clinical unit locations worldwide.

In addition, the CRO has signed a services work order related to the first study using QTinno, which is scheduled to be initiated this June.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.